uct patients to insert the canister back into the actuator after it is dry, and to re-prime BEVESPI AEROSPHERE. Instruct patients to re-prime BEVESPI AEROSPHERE by releasing 2 sprays into the air away from their face, shaking well before each spray.
Inform patients that if they miss a dose of BEVESPI AEROSPHERE, they should take their next dose at the usual time. Instruct patients to not use BEVESPI AEROSPHERE more often or more puffs than they have been prescribed.
Instruct patients not to spray BEVESPI AEROSPHERE in their eyes. Inform patients that if they accidentally get BEVESPI AEROSPHERE in their eyes, to rinse their eyes with water, and if redness or irritation persists, to consult their healthcare provider.
BEVESPI®, AEROSPHERETM and BEVESPI AEROSPHERETM are trademarks of the AstraZeneca group of companies.
©AstraZeneca 2016
Manufactured for:
AstraZeneca Pharmaceuticals LP,
Wilmington, DE 19850
By: Aventis Pharma LTD, Holmes Chapel CW48BE, United Kingdom
MEDICATION GUIDE
MEDICATION GUIDE
BEVESPI AEROSPHERE™
(be-VES-pee AIR-oh-sfeer)
(glycopyrrolate and formoterol fumarate)
inhalation aerosol, for oral inhalation use
What is the most important information I should know about BEVESPI AEROSPHERE?
BEVESPI AEROSPHERE is only approved for use in chronic obstructive pulmonary disease (COPD). BEVESPI AEROSPHERE is NOT approved for use in asthma.
BEVESPI AEROSPHERE can cause serious side effects, including:
•
People with asthma who take long-acting beta2-adrenergic agonist (LABA) medicines, such as formoterol fumarate (one of the medicines in BEVESPI AEROSPHERE), have an increased risk of death from asthma problems.
•
It is not known if LABA medicines, such as formoterol fumarate (one of the medicines in BEVESPI AEROSPHERE), increase the risk of death in people with COPD.
•
Call your healthcare provider if breathing problems worsen over time while using BEVESPI AEROSPHERE. You may need different treatment.
•
Get emergency medical care if:
° your breathing problems worsen quickly
° you use your rescue inhaler, but it does not relieve your breathing problems
What is BEVESPI AEROSPHERE?
BEVESPI AEROSPHERE combines an anticholinergic, glycopyrrolate, and a LABA medicine, formoterol fumarate.
•
Anticholinergic and LABA medicines help the muscles around the airways in your lungs stay relaxed to prevent symptoms such as wheezing, cough, chest tightness, and shortness of breath. These symptoms can happen when the muscles around the airways tighten. This makes it hard to breathe.
•
BEVESPI AEROSPHERE is a prescription medicine used to treat COPD. COPD is a chronic lung disease that includes chronic bronchitis, emphysema, or both.
•
BEVESPI AEROSPHERE is used long term as 2 inhalations, 2 times each day in the morning and in the evening, to improve symptoms of COPD for better breathing.
•
BEVESPI AEROSPHERE is not for use to treat sudden symptoms of COPD. Always have a rescue inhaler (an inhaled, short-acting bronchodilator) with you to treat sudden symptoms. If you do not have a rescue inhaler, contact your healthcare provider to have one prescribed for you.
•
BEVESPI AEROSPHERE is not for the treatment of asthma. It is not known if BEVESPI AEROSPHERE is safe and effective in people with asthma.
•
BEVESPI AEROSPHE
